LOAMU
CRSP icon

Lombard Odier Asset Management (USA)’s CRISPR Therapeutics CRSP Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-46,410
Closed -$1.33M – 254
2018
Q4 		$1.33M Sell
46,410
-53,590
-54% -$1.86M 0.1% 158
2018
Q3 		$4.43M Buy
+100,000
New +$5.24M 0.33% 101

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s CRSP Position: Q1 2019 in Review

Lombard Odier Asset Management (USA) sold out of CRISPR Therapeutics (CRSP) in Q1 2019, closing a stake of 46,410 shares — an estimated $1.33M sold.

Lombard Odier Asset Management (USA) first reported a position in CRSP in Q3 2018 and held it in 2 quarters. The position peaked at $4.43M in Q3 2018. 170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

  • Lombard Odier Asset Management (USA) reported no remaining CRISPR Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 46,410 CRISPR Therapeutics shares in Q1 2019, an estimated $1.33M.
  • Lombard Odier Asset Management (USA) first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 2 quarters.
  • Lombard Odier Asset Management (USA)'s CRISPR Therapeutics position peaked at $4.43M in Q3 2018.
  • 170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2019, filed 15 May 2019.